EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BB Biotech AG's Enterprise Value is CHF2,585.99 Mil.
BB Biotech AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was CHF218.28 Mil. Therefore, BB Biotech AG's EV-to-FCF for today is 11.85.
The historical rank and industry rank for BB Biotech AG's EV-to-FCF or its related term are showing as below:
XSWX:BION'
s EV-to-FCF Range Over the Past 10 Years
Min: -61.41 Med: 10.68 Max: 97.45
Current: 11.85
During the past 13 years, the highest EV-to-FCF of BB Biotech AG was 97.45. The lowest was -61.41. And the median was 10.68.
XSWX:BION's EV-to-FCF is ranked worse than 58.93% of 392
companies
in the Biotechnology industry
Industry Median: 4.22
vs XSWX:BION: 11.85
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), BB Biotech AG's stock price is CHF41.60.
BB Biotech AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-3.770. Therefore, BB Biotech AG's PE Ratio for today is At Loss.
BB Biotech AG EV-to-FCF Historical Data
The historical data trend for BB Biotech AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BB Biotech AG's EV-to-FCF
For the Biotechnology subindustry, BB Biotech AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BB Biotech AG's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BB Biotech AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BB Biotech AG's EV-to-FCF falls into.
BB Biotech AG EV-to-FCF Calculation
BB Biotech AG's EV-to-FCF for today is calculated as:
BB Biotech AG's current Enterprise Value is CHF2,585.99 Mil.
BB Biotech AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF218.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BB Biotech AG (XSWX:BION) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
BB Biotech AG's PE Ratio for today is calculated as:
BB Biotech AG's share price for today is CHF41.60.
BB Biotech AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-3.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BB Biotech AG EV-to-FCF Related Terms
Thank you for viewing the detailed overview of BB Biotech AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:BION has been successfully added to your 